ESC Premium Access

Older patients with atrial fibrillation and comorbidities are less likely to be treated with oral anticoagulation: insights from a nationwide study

Congress Session

About the speaker

Doctor Peter Vibe Rasmussen

Gentofte University Hospital, Copenhagen (Denmark)
0 follower

8 more presentations in this session

Oral anticoagulants in patients with atrial fibrillation having an intermediate risk of ischemic stroke but a high risk of bleeding

Speaker: Doctor T. Chao (Taipei, TW)

Thumbnail

Efficacy and safety of vernakalant for cardioversion of recent-onset atrial fibrillation in real-world clinical practice: the SPECTRUM post-approval safety study

Speaker: Professor J. Hartikainen (Kuopio, FI)

Thumbnail

Age-dependent anti-thrombotic therapy for atrial fibrillation patients with intermediate risk (CHA2DS2-VASc Score of 1 or 2) of ischemic stroke

Speaker: Associate Professor S. Choi (Busan, KR)

Thumbnail

Mortality in patients with non-valvular atrial fibrillation in South America. Warfarin has significant higher global mortality rates versus dabigatran and rivaroxaban

Speaker: Doctor G. Vanerio (Montevideo, UY)

Thumbnail

Effectiveness and safety of rivaroxaban versus warfarin in nonvalvular atrial fibrillation patients with coronary or peripheral artery disease

Speaker: Doctor C. Coleman (Storrs, US)

Thumbnail

Access the full session

Poster Session 5 - Atrial fibrillation and oral anticoagulation 4

Speakers: Doctor P. Rasmussen, Doctor T. Chao, Professor J. Hartikainen, Associate Professor S. Choi, Doctor G. Vanerio...
Thumbnail

About the event

Image

ESC CONGRESS 2019

31 August - 4 September 2019

Sessions Presentations

This platform is supported by

logo Novo Nordisk